NEW YORK, Oct. 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
European Pharmaceutical Market: Strategic Assessments of Leading Suppliers
This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market.
The report provides a worldwide strategic overview of the pharmaceutical market, including:
• Sales forecast for major product segments: ethical, OTC, generics.
• Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others.
In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies.
The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
The report's majorPage: 1 2 3 4 5 6 7 Related medicine technology :1
. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 20072
. Boston Scientific Announces Schedule for European Society of Cardiology Congress 20073
. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day4
. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology5
. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September6
. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)7
. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress8
. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System9
. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer10
. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy11
. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting